Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.51 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5948518 | 0.78 | GABRP (0.46) | IKBKEKDM4EMAPT | |
| SCHEMBL5947994 | 0.76 | ALOX5 (0.48) | MAP4K4IKBKEJAK2 | |
| SCHEMBL18371188 | 0.76 | PTGS1 (0.49) | IKBKEKDM4EMAPTADORA2AADORA1 | |
| SCHEMBL508694 | 0.75 | MAP4K4 (0.54) | DHFRMAP4K4ADORA2AADORA1JAK2 | |
| SCHEMBL20082997 | 0.74 | PTGS1 (0.47) | IKBKEKDM4EMAPTADORA2AADORA1 | |
| Ammonia Solution, Strong SCHEMBL3969114 | 0.74 | IKBKE (0.53) | DHFRMAP4K4IKBKEKDM4EL3MBTL1 | |
| SCHEMBL30301811 | 0.74 | NR1I3 (0.63) | MAP4K4KDM4EMAPTDPP4 | |
| SCHEMBL29446753 | 0.74 | ESR1 (0.56) | KDM4EADORA2AADORA1 | |
| SCHEMBL603134 | 0.74 | ESR1 (0.56) | KDM4EADORA2AADORA1 | |
| SCHEMBL18371197 | 0.73 | PTGS1 (0.46) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | LEXICON PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | LEXICON PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | TNF, IL6, CXCL8 | DHFR 1830/4885MAP4K4 2038/4885IKBKE 973/4885 |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | CPT1B, CPT1A, SHBG | DHFR 945/4885MAP4K4 2626/4885IKBKE 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.